Caribou Biosciences (NASDAQ:CRBU – Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.08, FiscalAI reports. The company had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million. Caribou Biosciences had a negative return on equity of 84.17% and a negative net margin of 1,189.14%.
Caribou Biosciences Stock Performance
Shares of Caribou Biosciences stock traded down $0.09 on Thursday, hitting $1.61. 1,131,465 shares of the company’s stock were exchanged, compared to its average volume of 1,560,761. Caribou Biosciences has a 1 year low of $1.38 and a 1 year high of $3.54. The company has a 50-day simple moving average of $1.70 and a 200-day simple moving average of $1.84. The stock has a market capitalization of $159.68 million, a PE ratio of -1.13 and a beta of 2.38.
Hedge Funds Weigh In On Caribou Biosciences
Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. boosted its holdings in shares of Caribou Biosciences by 80.0% during the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock valued at $39,000 after purchasing an additional 10,824 shares during the last quarter. Creative Planning bought a new stake in shares of Caribou Biosciences in the second quarter worth about $25,000. Invesco Ltd. increased its holdings in shares of Caribou Biosciences by 187.2% in the fourth quarter. Invesco Ltd. now owns 35,063 shares of the company’s stock worth $56,000 after purchasing an additional 22,856 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Caribou Biosciences during the second quarter valued at approximately $30,000. Finally, Credit Agricole S A purchased a new position in Caribou Biosciences during the 3rd quarter valued at approximately $68,000. 77.51% of the stock is owned by institutional investors.
Analyst Ratings Changes
About Caribou Biosciences
Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.
Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.
Featured Stories
- Five stocks we like better than Caribou Biosciences
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
